Home›Procedures›In Vitro Fertilization (IVF)

In Vitro Fertilization (IVF)

Eggs are retrieved from the ovaries after hormonal stimulation, fertilised with sperm in a laboratory, and one resulting embryo is transferred into the uterus.

Reproductive Ovaries, uterus and embryology laboratory Avg. stay 21 days 0 clinics

Overview

In vitro fertilisation (IVF) is an assisted reproductive technology in which oocytes are retrieved from controlled-hyperstimulated ovaries, combined with sperm in an embryology laboratory, and one or more resulting embryos are transferred into the uterus to achieve a clinical pregnancy. IVF is offered to couples with tubal-factor infertility, severe male-factor infertility (often with intracytoplasmic sperm injection, ICSI), endometriosis, anovulatory disorders unresponsive to ovulation induction, unexplained infertility, and patients using donor gametes or fertility preservation. A full IVF cycle takes about three to six weeks and follows six standard stages: pituitary suppression, controlled ovarian stimulation with follicle-stimulating hormone (FSH), monitoring by transvaginal ultrasound and serum oestradiol, ultrasound-guided transvaginal oocyte retrieval under sedation, laboratory fertilisation and embryo culture for 3-5 days, and transcervical embryo transfer. A pregnancy test is performed approximately two weeks after transfer. Live birth rates per started cycle depend strongly on female age, ranging from approximately 32 percent under 35 to under 5 percent above 44 in NHS reporting. International patients often combine a stimulation cycle in their home country with a treatment cycle abroad, or undertake the complete cycle at the destination clinic with a stay of about three weeks to align stimulation, retrieval and transfer. Embryos not transferred can be cryopreserved for future cycles. Sources: NHS, HFEA, NICE fertility guidance.

Hospital & stay

2–3 nights
Hospital stay
21 days
Total stay abroad
Reproductive
Procedure type

Procedure details

How it's performed

After down-regulation, daily subcutaneous FSH injections stimulate multifollicular development over 8-14 days, monitored by transvaginal ultrasound. A trigger injection (hCG or GnRH agonist) is given 36 hours before ultrasound-guided transvaginal needle aspiration of follicles under sedation. Oocytes are fertilised by conventional insemination or ICSI and cultured to day 3-5. One blastocyst is loaded into a soft catheter and transferred transcervically into the uterine cavity; remaining good-quality embryos are vitrified.

Preparation
  1. 1Pre-treatment investigations: ovarian reserve testing (AMH, antral follicle count), semen analysis, screening for blood-borne viruses, and pelvic ultrasound.
  2. 2Optimise BMI, stop smoking, limit caffeine and alcohol, and start folic acid 400 mcg daily.
  3. 3Counselling on success rates, multiple-pregnancy risk and ovarian hyperstimulation syndrome.
  4. 4Teaching session to learn self-administration of subcutaneous injections.
  5. 5Confirm a treatment calendar and arrange time off work for monitoring scans, egg collection and transfer.
Recovery
  1. 1Day of egg collection: Rest at the clinic for 1-2 hours under monitoring before discharge; mild cramping and spotting are normal.
  2. 2Days 1-5: Avoid strenuous exercise, heavy lifting and intercourse; continue luteal-phase progesterone support.
  3. 3Day of transfer: Brief outpatient procedure; resume light activity immediately.
  4. 4Days 1-14 after transfer: Normal daily activity; avoid alcohol and unprescribed medication.
  5. 5Day 12-14: Beta-hCG blood test to confirm pregnancy.
  6. 6Week 7: Early viability ultrasound scan if pregnant.

Before you travel: what the CDC recommends

The U.S. Centers for Disease Control and Prevention publishes guidance for Americans travelling abroad for medical care. These are its recommendations, not ours.

  • Check the qualifications of the clinician who will perform the procedure and the credentials of the facility.
  • Bring copies of your medical records, including lab and other test results related to your condition.
  • Make sure you can get follow-up care in the United States. Care for complications can be expensive and might not be covered by your health insurance.
  • Obtain international travel health insurance that covers medical evacuation back to the United States.
  • Plan for the possibility of paying out of pocket for additional or emergency care.
  • See your own healthcare provider 4–6 weeks before the trip to discuss risks specific to your health.
  • Delay air travel for 10–14 days after major surgery, particularly chest surgery, to reduce risks from changes in cabin pressure.

Source: CDC Travelers’ Health — Medical Tourism

In Vitro Fertilization (IVF) abroad: frequently asked questions

How much does in vitro fertilization cost in the U.S.?

Typically $15,000 to $30,000, according to IVFPath, 2026.

How long do I need to stay abroad for in vitro fertilization?

Plan on about 21 days, from arrival to the flight home. Your surgeon will confirm when it is safe to travel.

Will U.S. insurance pay for in vitro fertilization abroad?

Most U.S. health plans do not pay for elective surgery abroad, and cosmetic procedures are not covered at all. The CDC also warns that care for complications after surgery abroad may not be covered, so check your plan before you book.

What the research says about IVF and fertility treatment

14 peer-reviewed sources

In vitro fertilisation (IVF) is the most studied form of assisted reproductive technology, with a large evidence base from randomised trials, Cochrane reviews, and international guidelines. Success is most meaningfully described as the cumulative live birth rate across multiple cycles, which is strongly influenced by maternal age, ovarian reserve, and the underlying cause of infertility. Research continues to compare embryo transfer strategies, ovarian stimulation protocols, genetic testing, and frozen versus fresh transfers, while also monitoring safety issues such as ovarian hyperstimulation and perinatal outcomes. Because results vary considerably between individuals, evidence-based counselling and realistic expectations are essential. The references below are selected from peer-reviewed meta-analyses, Cochrane reviews, and guideline-level sources.

  1. ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025†.
    ESHRE Guideline Group on Ovarian Stimulation et al. · Human reproduction (Oxford, England) · 2026
    Clinical guidelinePMID 41732035DOI
  2. Endometrial injury in women undergoing in vitro fertilisation (IVF).
    Perera AK et al. · The Cochrane database of systematic reviews · 2026
    Cochrane systematic reviewPMID 42138348DOI
  3. Blastocyst-stage versus cleavage-stage embryo transfer in assisted reproductive technology.
    Glujovsky D et al. · The Cochrane database of systematic reviews · 2026
    Cochrane systematic reviewPMID 41574757DOI
  4. The effect of preimplantation genetic testing for aneuploidy (PGT-A) on obstetric and neonatal outcomes: a systematic review and meta-analysis.
    Hyttel CB et al. · Human reproduction (Oxford, England) · 2026
    Systematic review and meta-analysisPMID 41966094DOI
  5. Does preimplantation genetic testing for aneuploidy improve live birth rate in women diagnosed with recurrent implantation failure: A systematic review and meta-analysis?
    Newnham A et al. · Acta obstetricia et gynecologica Scandinavica · 2026
    Systematic review and meta-analysisPMID 41738632DOI

Compiled from peer-reviewed medical literature indexed on PubMed. This overview is for general education and is not medical advice. · Last updated 2026-06-15